Lords Mark Industries Limited (formerly Lords Mark India Limited and Kratos Energy & Infrastructure Limited) has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, alongside the detailed calendar for its 46th Annual General Meeting (AGM).

The Board of Directors approved the financial results during its meeting held on August 13, 2026. For the quarter, the company reported a total income from operations of ₹28,038.22 lakh on a standalone basis, compared to nil in the corresponding quarter of FY25. The net profit after tax stood at ₹3,216.44 lakh, marking a recovery from a net loss of ₹3.41 lakh in the same period last year.

Financial Performance Q1FY27

On a consolidated basis, total income from operations was ₹30,766.21 lakh. The consolidated net profit after tax was ₹3,318.23 lakh, up from a loss of ₹3.41 lakh in Q1FY25. Earnings per share (basic) were ₹0.75 on a standalone basis and ₹0.78 on a consolidated basis.

46th AGM Calendar and E-Voting

The 46th AGM is scheduled to be held on September 30, 2026, at 11:30 am through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The record date for determining voting eligibility is September 23, 2026.

Shareholders can participate in remote e-voting from September 27, 2026, to September 29, 2026, between 9:00 am and 5:00 pm each day. M/s National Securities Depository Limited (NSDL) serves as the E-Voting Service Provider, with Ms. Geeta Serwani appointed as the Scrutinizer.

Key Board Decisions and Auditor Appointments

The board noted the resignation of Ms. Bhavini Rajkumar Chandnani from the position of Company Secretary and Compliance Officer, effective August 20, 2026. Additionally, the board recommended several auditor appointments for shareholder approval:

• Statutory Auditor: M/s Sanjeev S. Gupta & Associates for a five-year term from the conclusion of the 46th AGM until the 51st AGM.
• Secretarial Auditor: M/s Geeta Serwani & Associates for five years covering FY27 to FY31.
• Internal Auditor: M/s E Srinivas and Co for three consecutive financial years (FY27 to FY29).
• Cost Auditor: M/s Raj Kaushik & Associates for FY27.

The board also authorized Chairman and Managing Director Sachidanand Upadhyay to take necessary decisions regarding the formation of subsidiaries, acquisitions, mergers, and demergers, as well as measures for restructuring the management team of Kratos Energy Infrastructure Limited. The trading window for dealing in the company's securities remains closed and will reopen 48 hours after the public release of the financial results.

Lords Mark Industries Limited announced a strategic restructuring plan involving the demerger of its renewable energy and LED division into a separate entity, Lords Shakti Power Limited. The move aims to allow the energy business to pursue its capital programme independently while enabling the remaining healthcare and diagnostics businesses to be valued on their own fundamentals.

The Board of Directors proposed that Lords Mark Industries will hold a 60% stake in the new entity, with existing shareholders receiving shares in proportion to their current holdings. The scheme is expected to be filed by March 2027. Lords Shakti Power Limited will also enter the power transmission business through transformer manufacturing.

Financial Guidance for FY27

The company issued financial guidance for FY27, projecting significant growth driven primarily by its base businesses of in vitro diagnostics (IVD) and renewable energy & LED. Management expects consolidated revenue of at least ₹1,550 crore, representing growth of over 20% compared to FY26. Profit after tax (PAT) is guided at a minimum of ₹178 crore, reflecting growth of over 50% and a margin inflection of at least 200 basis points.

Management indicated that material contribution from the sickle cell testing business and the medical devices segment—comprising Onco Spectra and TB Truth—is expected from FY28 onward, as these units commence meaningful commercialisation.

Strategic Expansions and Partnerships

Lords Mark outlined several strategic initiatives across healthcare delivery and diagnostics:

• CAR-T Cell Therapy: The company plans an exclusive India agreement with a leading global manufacturer to establish laboratory and treatment capabilities across five centres. The first two centres in Mumbai and Bangalore are targeted to commence by March 2027, offering treatment at a substantially lower price point than currently available.
• International Subsidiaries: Lords Mark Industries UK Limited has been incorporated as the first Indian company to register in the UK following the India-UK Free Trade Agreement. It aims to be operational from January 2027, running a pathology laboratory supplied by the company’s Indian manufacturing base. A similar subsidiary is being established in Switzerland to extend regulated-market presence into continental Europe.
• Oncology Hospitals: Through subsidiary Lords Mark Medicine Limited, the company plans to launch owned oncology hospitals in tier-2 cities. Two pilot hospitals of approximately 70 beds each in Vapi and Solapur are targeted to open by March 2027, funded through a debt raise of approximately ₹200 crore in December 2026.
• Dialysis Network: The company proposes to establish 50 dialysis centres across India by March 2027. Operating from rented premises and equipped with its own RENALOS dialysis machines, this model shifts the business from equipment sales toward recurring, session-based service revenue.

Regulatory Approvals and Product Launches

Lords Mark reported regulatory milestones for its diagnostic platforms:

• OneDNA Genomic Testing: Patient trials for the OneDNA genomic testing platform have been completed, and approval has been received from the Indian Council of Medical Research (ICMR). An application to the Central Drugs Standard Control Organisation (CDSCO) is currently under process.
• Biomescan Analytics Platform: The company received a manufacturing licence for its Biomescan Analytics Platform, becoming the first and only company in India to receive such a licence for In Vitro Diagnostic Software (Software as a Medical Device – SaMD) under the Medical Devices Rules, 2017.

What the Numbers Show

The guidance indicates a divergence between top-line and bottom-line growth trajectories for FY27. While revenue is projected to grow over 20%, PAT is expected to grow over 50%. This acceleration in profitability, alongside a margin expansion of at least 200 basis points to 11.4%, suggests that the company anticipates operating leverage or improved cost structures in its core IVD and renewable energy segments, rather than pure volume-driven growth alone.